Table 3.
Propensity score-matched patients | |||||
---|---|---|---|---|---|
Variable | Total | Right-side colon | Left-side colon | Rectum | P-value, chi-square |
Number of patients | 487 | 136 | 172 | 179 | |
Age | |||||
≤50 y | 230 | 67 | 85 | 78 | 0.787 |
51-65 y | 176 | 46 | 61 | 69 | |
>65 y | 81 | 23 | 26 | 32 | |
Gender | |||||
Male | 302 | 78 | 107 | 117 | 0.348 |
Female | 185 | 58 | 65 | 62 | |
Mucinous histology | |||||
Yes | 81 | 27 | 30 | 24 | 0.295 |
No | 406 | 109 | 142 | 155 | |
Stage at diagnosis | |||||
I | 6 | 1 | 1 | 4 | <0.001 |
II | 48 | 13 | 11 | 24 | |
III | 163 | 39 | 47 | 77 | |
IV | 270 | 83 | 113 | 74 | |
First line therapy | |||||
Chemotherapy | 243 | 58 | 86 | 99 | 0.084 |
Bevacizumab + chemotherapy | 244 | 78 | 86 | 80 | |
Metastatic organ | |||||
1 | 345 | 100 | 115 | 130 | 0.662 |
>1 | 142 | 36 | 57 | 49 | |
CEA | |||||
≤5 ng/ml | 138 | 31 | 53 | 54 | 0.216 |
>5 ng/ml | 346 | 105 | 117 | 124 | |
unknown | 3 | 0 | 2 | 1 | |
LDH | |||||
≤245 U/ml | 346 | 101 | 114 | 131 | 0.262 |
>245 U/ml | 140 | 35 | 57 | 48 | |
unknown | 1 | 0 | 1 | 0 | |
Backbone chemotherapy | |||||
Oxaliplatin-based | 190 | 52 | 72 | 66 | 0.903 |
Irinotecan-based | 257 | 73 | 87 | 97 | |
5-fluorouracil only | 40 | 11 | 13 | 16 | |
Bevacizumab beyond first line | |||||
Yes | 57 | 18 | 152 | 160 | 0.773 |
No | 430 | 118 | 20 | 19 | |
Cetuximab treated | |||||
Yes | 55 | 13 | 21 | 21 | 0.655 |
No | 432 | 123 | 151 | 158 | |
Primary tumor resection | |||||
Yes | 166 | 43 | 54 | 69 | 0.285 |
No | 321 | 93 | 118 | 110 |